Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:CODX

Co-Diagnostics Q3 2026 Earnings Date & Estimates

Co-Diagnostics logo
$0.55 -0.02 (-4.30%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$0.55 +0.00 (+0.27%)
As of 10/23/2026 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Co-Diagnostics is estimated to report Q3 2026 earnings on Monday, November 16, 2026. The conference call is scheduled for November 12, 2026 at 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Co-Diagnostics in Q3 2026

Co-Diagnostics is expected to post earnings of -$1.25 per share on revenue of $0.17 million. In the same quarter a year earlier Co-Diagnostics reported -$4.80 per share on revenue of $0.15 million. Co-Diagnostics last reported on August 13, 2026, posting -$1.46 per share and beating the -$3.00 consensus estimate. Co-Diagnostics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.25
Expected Revenue
$0.17 million
Prior-Year EPS
-$4.80
Prior-Year Revenue
$0.15 million
Expected Revenue Growth
+16.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.46 (Beat by +$1.54)
Last Quarter Revenue
$0.17 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Co-Diagnostics Q3 2026 Earnings FAQ

Co-Diagnostics (NASDAQ:CODX) is estimated to report Q3 2026 earnings on Monday, November 16, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Co-Diagnostics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Co-Diagnostics to post earnings of -$1.25 per share for Q3 2026.

The consensus revenue estimate for Co-Diagnostics is $0.17 million for Q3 2026.

Co-Diagnostics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Co-Diagnostics on the company's earnings history page.

Co-Diagnostics Earnings Headlines

Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
October 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-comira-diagnostics-invited-by-saudi-ministry-to-participate-in-strategic-manufacturing-forum-302913915.html
Head to Head Review: Neuphoria Therapeutics (NASDAQ:NEUP) and Co-Diagnostics (NASDAQ:CODX)
October 19, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31134070
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
October 24 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Co-Diagnostics Plans Special Meeting After Quorum Shortfalls
October 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CODX/pressreleases/8113327/co-diagnostics-plans-special-meeting-after-quorum-shortfalls/
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
October 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/co-diagnostics-highlights-pcr-platform-capabilities-for-potential-plague-detection-302909363.html
Co-Diagnostics Expands Vector Smart With First Tribal Laboratory Installation
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697642/co-diagnostics-expands-vector-smart-with-first-tribal-laboratory-installation.aspx
See More Co-Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email.

About Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX) is a molecular diagnostics company headquartered in Salt Lake City, Utah. The company develops and commercializes diagnostic technologies and laboratory tests designed to identify infectious diseases and other medical conditions using polymerase chain reaction (PCR) and related molecular methods.

Its core technology is the CoPrimer platform, which is intended to support the development of accurate, cost-efficient molecular diagnostic tests. Co-Diagnostics has marketed tests under the Logix Smart brand, including assays for respiratory and other infectious diseases. The company also developed molecular testing products related to COVID-19 and has pursued diagnostic applications in areas such as tuberculosis, mosquito-borne diseases, women’s health and oncology.

Co-Diagnostics was founded in 2013 and serves customers through commercial, laboratory and distribution channels in the United States and international markets. Its products are designed for use by clinical laboratories, healthcare providers and other testing organizations, with availability varying by product, regulatory authorization and geography. Dwight E. Hurst is a co-founder and has served as the company’s chief executive officer.

View Co-Diagnostics Profile
Earnings Tools